top of page

Browse by category

Search

AstraZeneca enters obesity market with $2b deal for GLP-1 candidate

AstraZeneca enters obesity market with $2b deal for GLP-1 candidate

AstraZeneca has signed an exclusive license agreement with Shanghai-based biotech Eccogene for ECC5004, an early-stage investigational...

AstraZeneca and Regeneron to develop obesity treatments

AstraZeneca and Regeneron to develop obesity treatments

AstraZeneca has entered into a collaboration with Regeneron to research, develop and commercialise small molecule compounds directed...

Stent-Over-Sponge as a rescue technique for leak post-bariatric surgery

2 hours ago

STEP UP: Semaglutide 7.2mg achieves 20.7% weight loss and 18.7% regardless of treatment adherence

3 hours ago

GLP-1ra linked to cognitive benefits but could increase risk of pancreatitis and kidney conditions

3 hours ago

bottom of page